No­vo Nordisk con­tin­ues to grap­ple with patchy GLP-1 drug sup­ply in Eu­rope

All dos­es of No­vo Nordisk’s Ozem­pic are ex­pect­ed to face “in­ter­mit­tent short­ages” in Eu­rope dur­ing the fourth quar­ter of the year, es­pe­cial­ly low­er dos­es, sup­plies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER